JNPMEDI has announced the launch of its new 'Total Digital Medical Business Boosting Solution' service on May 9th.
This new service aims to expand the company's market influence by extending its business into the consulting domain.
The 'Total Digital Medical Business Boosting Solution' leverages JNPMEDI’s proprietary clinical trial solution, Maven Clinical Cloud, to provide comprehensive consulting services for the commercialization of pharmaceuticals and medical devices.
This all-encompassing service supports every fragmented business area from product planning and operational strategy development to regulatory approval and licensing.
JNPMEDI has been continuously enhancing its organizational capabilities to establish a comprehensive solution service that addresses all stages of the life sciences industry.
Since its inception, JNPMEDI has recruited leading experts across various fields, including clinical trials, management consulting, IT, and law, to design and deliver customized services tailored to individual client needs.
The company’s service portfolio now includes: ▲ Comprehensive drug and medical device development (CDMO) covering product development, validation, clinical trials, commercialization, and post-market management; ▲Digital technology-based total Clinical Research Organization (CRO) services; ▲ Strategic investment and licensing planning.
The new service is expected to significantly aid clients struggling with entering clinical trials and commercializing pharmaceuticals and medical devices. Leveraging JNPMEDI's advanced digital technology for clinical operations and data management solutions, the service facilitates decision-making across consulting processes, thereby minimizing errors in the commercialization process, enhancing operational efficiency, and reducing costs.
Clients can also achieve accelerated and guided progress toward their goals with support from a dedicated team possessing extensive knowledge, experience, and expertise across various fields. Another significant advantage is the ability to utilize JNPMEDI’s global network, including partnerships with US, Australian, and European CRO firms.
Furthermore, JNPMEDI’s recent initiative to directly invest in biotech and medical device companies and match them with investors offers clients additional opportunities for funding.
The market has responded promptly to this high-focus service, which simultaneously drives medical digital transformation (DX) and business acceleration. JNPMEDI is currently applying this new service in collaboration with SoluM Healthcare to develop and commercialize a sensor-based rapid cancer diagnostic solution.
Earlier this year, JNPMEDI signed an MOU with SoluM Healthcare for collaboration on the cancer diagnostics business, covering various areas such as clinical trials, medical device regulatory approval, and domestic and international market expansion. JNPMEDI plans to further broaden its network of partnerships based on the newly introduced service.
Kwunho Jeong, CEO of JNPMEDI, stated, “We launched this new solution to help companies overcome business uncertainties by closely linking significant insights gained from the valuable experiences and technology-intensive solutions of our experts to practical business processes. By continually refining our new service, we aim to become the optimal partner and accelerator for the growth of pharmaceutical and medical device companies both domestically and internationally, while creating synergistic advancements that contribute to the innovative development of the life sciences industry.”
JNPMEDI has announced the launch of its new 'Total Digital Medical Business Boosting Solution' service on May 9th.
This new service aims to expand the company's market influence by extending its business into the consulting domain.
The 'Total Digital Medical Business Boosting Solution' leverages JNPMEDI’s proprietary clinical trial solution, Maven Clinical Cloud, to provide comprehensive consulting services for the commercialization of pharmaceuticals and medical devices.
This all-encompassing service supports every fragmented business area from product planning and operational strategy development to regulatory approval and licensing.
JNPMEDI has been continuously enhancing its organizational capabilities to establish a comprehensive solution service that addresses all stages of the life sciences industry.
Since its inception, JNPMEDI has recruited leading experts across various fields, including clinical trials, management consulting, IT, and law, to design and deliver customized services tailored to individual client needs.
The company’s service portfolio now includes: ▲ Comprehensive drug and medical device development (CDMO) covering product development, validation, clinical trials, commercialization, and post-market management; ▲Digital technology-based total Clinical Research Organization (CRO) services; ▲ Strategic investment and licensing planning.
The new service is expected to significantly aid clients struggling with entering clinical trials and commercializing pharmaceuticals and medical devices. Leveraging JNPMEDI's advanced digital technology for clinical operations and data management solutions, the service facilitates decision-making across consulting processes, thereby minimizing errors in the commercialization process, enhancing operational efficiency, and reducing costs.
Clients can also achieve accelerated and guided progress toward their goals with support from a dedicated team possessing extensive knowledge, experience, and expertise across various fields. Another significant advantage is the ability to utilize JNPMEDI’s global network, including partnerships with US, Australian, and European CRO firms.
Furthermore, JNPMEDI’s recent initiative to directly invest in biotech and medical device companies and match them with investors offers clients additional opportunities for funding.
The market has responded promptly to this high-focus service, which simultaneously drives medical digital transformation (DX) and business acceleration. JNPMEDI is currently applying this new service in collaboration with SoluM Healthcare to develop and commercialize a sensor-based rapid cancer diagnostic solution.
Earlier this year, JNPMEDI signed an MOU with SoluM Healthcare for collaboration on the cancer diagnostics business, covering various areas such as clinical trials, medical device regulatory approval, and domestic and international market expansion. JNPMEDI plans to further broaden its network of partnerships based on the newly introduced service.
Kwunho Jeong, CEO of JNPMEDI, stated, “We launched this new solution to help companies overcome business uncertainties by closely linking significant insights gained from the valuable experiences and technology-intensive solutions of our experts to practical business processes. By continually refining our new service, we aim to become the optimal partner and accelerator for the growth of pharmaceutical and medical device companies both domestically and internationally, while creating synergistic advancements that contribute to the innovative development of the life sciences industry.”